Methods of conditioning patients for T cell therapy
AssigneesKite Pharma, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsAdrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
Life of this patent
Estimating the term…
Abstract
The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
Claims30
A method of treating a patient having a tumor comprising (i) administering to the patient a dose of cyclophosphamide at about 500 mg/m2/day to about 600 mg/m2/day and a dose of fludarabine at about 30 mg/m2/day and (ii) administering to the patient a therapeutically effective amount of from about 1×106 to about 5×106 engineered CAR T cells/kg;
- wherein the dose of cyclophosphamide is administered daily for three days.
A method of conditioning a patient in need of a T cell therapy comprising (i) administering to the patient a dose of cyclophosphamide at about 500 mg/m2/day and to about 600 mg/m2/day and a dose of fludarabine at about 30 mg/m2/day;
- and
- (ii) administering to the patient a therapeutically effective amount of engineered CAR T cells;
- wherein the dose of cyclophosphamide is administered daily for three days.
A method of treating a patient having a tumor comprising (i) administering to the patient a dose of cyclophosphamide at about 500 mg/m2/day and a dose of fludarabine at about 30 mg/m2/day and (ii) administering to the patient a therapeutically effective amount of engineered CAR T cells, wherein the dose of cyclophosphamide is administered daily for three days.
A method of treating a patient having a tumor comprising (i) administering to the patient a dose of cyclophosphamide at about 600 mg/m2/day and a dose of fludarabine at about 30 mg/m2/day and (ii) administering to the patient a therapeutically effective amount of engineered CAR T cells;
- wherein the dose of cyclophosphamide is administered daily for about three days;
- and
- wherein the dose of fludarabine is administered daily for about three days.
Dependencies are inferred from the claim text.